Deals
The Dawn of a New Age of Megamerger?
The big news this week of the GSK–Novartis asset swap and rumors of a Pfizer bid for AstraZeneca prompted many a commentator to speculate that reports of the megamerger’s death may have been greatly exaggerated ...Read more
Marketing to Professionals
Are Drug Ads in Print Journals Still Effective?
If the American public could shed girth as quickly as many medical journals have in recent years, we’d all be a lot healthier. Collectively, medical journals dropped over 4,200 pages in 2013. But marketers should think twice about cutting off print journal plays
...Read more
Adam Smith Conferences’ Russian Pharmaceutical Forum
Fresh and innovative programme offers plenty of topics and themes to stimulate lively and constructive discussions. HEARover 100 expert speakers (Novartis, AstraZeneca, Pfizer, Teva, Stada, Takeda, Dr.Reddys), EXPERIENCE sessions sharing the best pharmaceutical practices (Generics vs Brands, Biogeneric Producers vs Biological Innovators, Patient Advocacy), LISTEN to special guest addresses (Multichannel Marketing Strategy) and GATHER inspirational ideas from executive debates (Distribution Strategy).
Date: June 17 - 19, 2014
Location: St.Petersburg, Russia
Venue: Corinthia St.Petersburg Hotel
Contact: Lyudmyla Durneva
+44 (0) 207 551 9065
Lyudmyla@adamsmithconferences.com
Website: www.adamsmithconferences.com/as2279PHEX
Patient Information
Will Pharma Help to Fix Wikipedia?
Will Pharma join a growing effort to make the world's leading online health information resource more relevant to providers and safer for patients? Peter Houston reports ...Read more
Pricing
Medicare Data Raises Questions about Drug Costs
The recently released Medicare data on payments to individual doctors doesn’t provide specifics on prescription drug outlays, but opens the door to scrutiny of Medicare reimbursement for medicines delivered in physician offices, writes Jill Wechsler ...Read more
White Paper – Reprints at the Dawn of the 'Sunshine Act'
Medical journal article reprints provide health care professionals credible clinical evidence that a product works. Read about the new reprint regulations emerging from the Physician Payment Sunshine Act. Learn about newer ePrint formats and discover new distribution channels to get the right article to the right prescriber at the right time. Read more
Pricing
Is Gilead’s $1000 Pill Worth It?
The Department of Veterans Affairs and other California panels’ solution to the new and extremely costly hepatitis (Hep) C drugs (Sovaldi and Olysio) is to reserve them for the patients with advanced liver diseases, including those awaiting transplants. What should patients with “milder” cases do then? ...Read more
Global
Market Access in Latin American: Specialty Products
Andrea Sobrio and Dr Sandra Schoenes examine the market access challenges and opportunities specifically for premium, specialty inpatient drugs in the Latin American region ...Read more
Leadership
Pharm Exec’s Emerging Pharma Leaders 2014 — Nominate Now
It's time for you to tell us who you think should receive Pharm Exec's 2014 Emerging Pharma Leadership Award. Read more for details of how to nominate a colleague — or yourself. ...Read more |
